On May 15, 2020 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that clinical and non-clinical data on BTK inhibitor BRUKINSA (zanubrutinib) and clinical data on anti-PD-1 antibody tislelizumab will be presented in an oral presentation and eight posters at the 25thEuropean Hematology Association (EHA) (Free EHA Whitepaper) Virtual Congress, taking place on June 11-14, 2020 (Press release, BeiGene, MAY 14, 2020, View Source [SID1234558062]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation:

Title: ASPEN: Results of a Phase 3 Randomized Trial Of Zanubrutinib Versus Ibrutinib for Patients with Waldenström Macroglobulinemia (WM)
Abstract #: S225
Session Title: Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical
Presenter: Meletios Dimopoulos, M.D., National and Kapodistrian University of Athens, Greece
Poster Presentations:

Title: Updated Results of the ASPEN Trial from a Cohort of Patients with MYD88 Wild-Type Waldenström Macroglobulinemia
Abstract #: EP1180
Session Title: Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical
Lead Author: Meletios Dimopoulos, M.D., National and Kapodistrian University of Athens, Greece

Title: Three-Year Follow-Up of Treatment-Naïve and Previously Treated Patients with Waldenström Macroglobulinemia (WM) Receiving Single Agent Zanubrutinib
Abstract #: EP1168
Session Title: Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical
Lead Author: Stephen Opat, MBBS, Monash University, Australia

Title: Phase 1/2 Study of Single-Agent Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Abstract #: EP1165
Session Title: Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical
Lead Author: Alessandra Tedeschi, M.D., Niguarda Cancer Center, Italy

Title: Tislelizumab (BGB-A317) for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study
Abstract #: EP1268
Session Title: Aggressive Non-Hodgkin Lymphoma – Clinical
Lead Author: Huiqiang Huang, M.D., Ph.D., Sun Yat-sen University Cancer Center, China

Title: Tislelizumab (BGB-A317) for Relapsed/Refractory Peripheral T-Cell Lymphomas: Safety and Efficacy Results from a Phase 2 Study
Abstract #: EP1235
Session Title: Aggressive Non-Hodgkin Lymphoma – Clinical
Lead Author: Pier Luigi Zinzani, M.D., Ph.D., University of Bologna, Italy

Title: Biomarker Identification in Relapsed/Refractory Non-Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma Treated with Zanubrutinib
Abstract #: EP1246
Session Title: Aggressive Non-Hodgkin Lymphoma – Clinical
Lead Author: Haiyan Yang, M.D., Zhejiang Cancer Hospital, China

Title: Zanubrutinib (BGB-3111) in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Abstract #: EP1271
Session Title: Aggressive Non-Hodgkin Lymphoma – Clinical
Lead Author: Jianfeng Zhou, M.D., Tongji Medical College, China

Title: Outcomes of Relapsed/Refractory MCL Patients Treated with Zanubrutinib Monotherapy in the Second Line and in Later Lines: A Pooled Analysis from 2 Studies
Abstract #: EP1169
Session Title: Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical
Lead Author: Keshu Zhou, M.D., Henan Cancer Hospital, China